Endothelial dysfunction is an early feature of vascular disease induced by cardiovascular risk factors (CRFs). In growing populations with obesity, diabetes, hypertension, and heart failure, mineralocorticoid receptor antagonism improves endothelial function. This review summarizes recent advances in our understanding of the specific role of endothelial cell mineralocorticoid receptor in vascular function in health and disease.
INTRODUCTION
The vasculature is lined with endothelial cells that dynamically regulate vascular tone, stiffness, inflammation, and thrombotic potential in health and disease. Through these functions, the endothelium contributes to regulation of organ blood flow, blood pressure (BP), and vascular integrity. Endothelial function is influenced by paracrine and circulating factors regulating the production and activity of endothelium-derived vasoactive and growth factors, adhesion molecules that mediate leucocyte-endothelial cell interaction, and regulators of blood coagulation. In the healthy vasculature, the endothelium is anti-inflammatory, antithrombotic and promotes vasodilation. In the presence of cardiovascular risk factors (CRFs), the endothelium becomes pro-inflammatory and pro-thrombotic and is characterized by impaired endothelium-dependent relaxation, a marker of endothelial dysfunction that predicts cardiovascular risk [1, 2] . The mechanism by which the healthy endothelium becomes dysfunctional in response to CRFs is not completely understood.
Endothelial dysfunction occurs in response to common CRFs including obesity, metabolic syndrome, hypertension, and heart failure. These conditions are all also associated with increased levels of the BP-regulating hormone aldosterone and activation of its mineralocorticoid receptor [3] . In patients with these conditions, mineralocorticoid receptor antagonism improves endothelial function [4,5,6 && ]. In addition to its role in controlling renal salt and water homeostasis, mineralocorticoid receptor is also expressed in the vascular endothelium [7, 8] . Recent reports that perivascular tissue is a paracrine source of mineralocorticoid receptor ligands in obesity [9] , and hyperadrenergic states [10] further supports the potential for direct vascular mineralocorticoid receptor activation to contribute to vascular disease in high-risk patients. However, the specific role of endothelial cell mineralocorticoid receptor in vascular health and disease has been controversial until recently [8] . The development of transgenic mice in which mineralocorticoid receptor expression can be specifically modulated in endothelial cells has recently advanced our understanding of the role of endothelial cell mineralocorticoid receptor in maintaining a healthy vasculature and its contribution to cardiovascular disease. This review summarizes our understanding of the role of endothelial mineralocorticoid receptor in vascular function and disease with an emphasis on data published in the past year.
PHYSIOLOGICAL VERSUS PATHOLOGICAL ROLE OF MINERALOCORTICOID RECEPTOR IN ENDOTHELIAL FUNCTION: STILL A PARADOX?
Early studies investigating the role of endothelial cell mineralocorticoid receptor in endothelial function produced conflicting findings (reviewed in [3, 11] ). Aldosterone can induce either vasoconstriction or vasodilation in isolated vessels (reviewed in [8, 12] ). Rapid vasodilator action of aldosterone was described to be dependent on mineralocorticoid receptor activation of PI3-kinase/Akt signaling, enhancing the production of the endotheliumderived vasodilator nitric oxide (NO) via phosphorylation of endothelial NO synthase (eNOS, Fig. 1 ) [12, 13] . However, when tested in vitro, endothelial cell mineralocorticoid receptor activation decreased eNOS activity is some studies [14, 15] while it enhanced eNOS-derived NO production in others [16] .
Clinical studies also originally appeared contradictory. Several studies reveal a protective role of mineralocorticoid receptor on endothelial function in healthy populations. Acute and chronic mineralocorticoid receptor activation in healthy men improved endothelium-dependent relaxation and enhanced NO bioactivity [17] . Accordingly, shortterm mineralocorticoid receptor antagonism with eplerenone impaired endothelial function in healthy older adults, as measured by brachial artery flow-mediated dilation (FMD), in association with reduced eNOS activity as determined by decreased eNOS Ser1177-phosphorylation [18 & ]. In another study, mineralocorticoid receptor inhibition improved FMD; however, the degree of improvement correlated with increased adiposity and fasting glucose, with no effect on vasorelaxation in nonobese patients [19] . This apparent contradiction is consistent with the emerging concept that although endothelial cell mineralocorticoid receptor may be protective in a healthy population, in the presence of CRFs (e.g., obesity, metabolic syndrome), endothelial cell mineralocorticoid receptor becomes a contributing factor to endothelial dysfunction. This is consistent with previous studies demonstrating that mineralocorticoid receptor antagonism improves endothelial function in heart failure patients [4] , and with a more recent reports showing that spironolactone improved coronary flow reserve (CFR) in patients with diabetes [6 && ] and enhanced endothelial progenitor cells -derived NO production in patients with hypertension due to hyperaldosteronism [20 && ]. Overall, clinical studies reveal that mineralocorticoid receptor inhibition in patients with cardiovascular disease or risk factors improves endothelial function. However, these studies cannot differentiate between direct effects of endothelial cell mineralocorticoid receptor or secondary effects on the endothelium mediated by mineralocorticoid receptor in other tissues. To address this, genetic mouse models have been developed with endothelial cellspecific mineralocorticoid receptor deletion. The
KEY POINTS
In the healthy vasculature, endothelial cell mineralocorticoid receptor exerts a minimal or protective impact on endothelial function.
In the setting of cardiovascular risk factors, endothelial cell mineralocorticoid receptor contributes to endothelial dysfunction, vascular stiffness, vascular inflammation, and thrombosis.
Mechanisms involved in endothelial cellmineralocorticoid receptor-induced vascular dysfunction include eNOS uncoupling, NADPH oxidase activation, ENaC-mediated endothelial stiffening, and ICAM-1-mediated vascular inflammation.
Differences in vascular health, sex, race, vessel size, and vascular bed might explain the controversial role of endothelial cell mineralocorticoid receptor in vascular health and disease.
first mouse model used the Tie2 promoter driving Cre recombinase expression resulting in mineralocorticoid receptor deletion from endothelial cell as well as leukocytes (due to Tie2 expression in bone marrow-derived cells). In this model, Schäfer et al. [21] found normal endothelium-dependent relaxation in aortae of healthy endothelial cell mineralocorticoid receptor, whereas Rickard et al. [22] found vasodilation to be reduced in the aorta and mesenteric arteries, with no change in BP or vasoconstriction (Table 1) . Because mineralocorticoid receptor activation promotes macrophage activation and T lymphocyte differentiation [29] , mineralocorticoid receptor deletion in leukocytes could have independently influence endothelial function in this model.
To address this controversy, a truly endothelial cell-specific mineralocorticoid receptor knockout mouse model (vascular endothelial-cadherin promoter driven Cre recombinase) was recently developed with intact leukocyte mineralocorticoid receptor [24 & ]. In this model, endothelial cell mineralocorticoid receptor deletion did not contribute to BP or to endothelial-dependent relaxation of coronary or mesenteric arteries in healthy animals. However, mesenteric arteries from male endothelial cell mineralocorticoid receptor knockout mice were protected from endothelial dysfunction following exposure to angiotensin II-induced hypertension . This is consistent with data in the Tie2-Cre/endothelial cell mineralocorticoid receptor knockout model showing that aortic endothelial function was unchanged in healthy mice lacking endothelial cell mineralocorticoid receptor, but these mice were protected from endothelial dysfunction caused by high fat diet-induced obesity [21] (Table 1) .
These clinical and animal studies support an emerging paradigm in which basal endothelial cell mineralocorticoid receptor activity may contribute to normal vasodilation without determining vascular tone or BP, but that endothelial cell mineralocorticoid receptor contributes to the extent of endothelial dysfunction in the setting of CRFs such as hypertension, obesity, and diabetes ( Fig. 1) . ]. Significantly, in a mouse model of Western diet-induced obesity, females developed higher plasma aldosterone levels compared with males [26, 32] perhaps due to estrogen regulation of adrenal aldosterone production [33] . Consistent with this, improvement of endothelial function with mineralocorticoid receptor blockade was more prominent in female compared with male hyperleptinemic mice [34 & ]. Female endothelial cell mineralocorticoid receptor knockout mice were also protected from increased endothelial stiffness and endothelial dysfunction induced by Western diet, further supporting a direct role for endothelial cell mineralocorticoid receptor in obesity-induced endothelial dysfunction [25 & ]. These studies suggest sex differences in the role of endothelial cell mineralocorticoid receptor in endothelial dysfunction, although the molecular mechanisms are still being explored. In human endothelial cells in vitro, activated estrogen receptor has been shown to inhibit the transcriptional activity of mineralocorticoid receptor [35] , providing another potential mechanism for sex differences in the role of mineralocorticoid receptor in endothelial cell function. Human coronary endothelial cells have been shown to express the cortisol-inactivating enzyme 11bHSD-2 supporting that aldosterone can act as a ligand for endothelial cell mineralocorticoid receptor ( [7] and reviewed in [8] ). However, whether 11bHSD-2 expression and/or function is modified by risk factors or other biological variables is not known and hence the potential for corticosteroids to activate endothelial cell mineralocorticoid receptor in vivo under different circumstances cannot be ruled out.
In contrast to the protective role of mineralocorticoid receptor activation in brachial artery FMD observed in previous studies of healthy populations [18 & ,36] , normotensive African-Americans developed endothelial microvascular dysfunction (evaluated by digital pulse arterial tonometry) in response to acute aldosterone administration, and this was prevented by spironolactone [37 & ]. It was suggested that the endothelial dysfunction in healthy African-Americans may be due to decreased vascular G6PD activity in this population. Aldosterone has previously been shown to suppress G6PD expression in endothelial cells [15] , supporting a potential direct role for endothelial cell mineralocorticoid receptor in the mechanism. This detrimental effect of acute aldosterone administration seen in healthy African-Americans was not observed in brachial artery FMD in a predominantly white male population [17] . However, since these studies examined microvessel dysfunction in African-Americans and large vessels in the white populations, further studies are needed to clarify whether there are indeed racial differences in the vascular response to aldosterone or alternatively, a higher susceptibility of resistance microvessels to endothelial dysfunction in response to endothelial cell mineralocorticoid receptor activation when compared with large conduit vessels like the aorta or brachial arteries.
Indeed, clinical and animal data support differences in the role of endothelial cell mineralocorticoid receptor in conduit compared with microvessel function. Garg et al. [6 && ] observed that mineralocorticoid receptor antagonism in people with type 2 diabetes improved CFR, an indicator of coronary microvascular function. The coronary benefits contrast with studies showing no improvement in forearm FMD with mineralocorticoid receptor blockade in patients with diabetes [38, 39] , metabolic syndrome [40] , or coronary artery disease [41] . These differences in the role of mineralocorticoid receptor may be due to mechanistic differences in regulation of the coronary versus peripheral vasculature. Indeed, the role of endothelial cell mineralocorticoid receptor in hypertension-induced vascular dysfunction in mice differed in the coronary compared with the mesenteric microvasculature in the endothelial cell-specific mineralocorticoid receptor knockout mouse model [24 & ] ( Table 1) . Further studies are needed to determine the mechanism for the distinct response to risk factors in the endothelium of different vascular beds and the role of endothelial cell mineralocorticoid receptor in mediating these differences.
NEW INSIGHTS INTO MECHANISMS FOR THE ROLE OF ENDOTHELIAL CELL MINERALOCORTICOID RECEPTOR IN ENDOTHELIAL FUNCTION
Overall, clinical and experimental data support that mineralocorticoid receptor blockade with spironolactone or eplerenone improves endothelial function in humans and animal models with high cardiovascular risk (reviewed in [3, 11] ). Tissuespecific knockout mice suggest a role for endothelial cell mineralocorticoid receptor in this protective effect (Table 1) . Although our understanding is still limited, the available data regarding the molecular mechanisms by which endothelial cell mineralocorticoid receptor contributes to endothelial dysfunction in the setting of cardiovascular disease are summarized in the following sections and depicted in Fig. 1 .
Endothelial cell mineralocorticoid receptor contributes to vascular oxidative stress and impaired NO bioavailability
In the healthy endothelium, NO is produced by eNOS and diffuses to the underlying smooth muscle cells, where it mediates vasodilation. NO also acts locally on endothelial cells to prevent inflammation and thrombosis. In the setting of cardiovascular disease risk factors, NO production and bioavailability are impaired. Production of NO may decrease due to a decline in eNOS expression or activity, as indicated by phosphorylation of Ser1177. eNOS functions as a dimer and in the setting of vascular disease may also become uncoupled due to a decrease in the eNOS cofactor BH 4 resulting in superoxide anion generation by eNOS rather than NO production. Superoxide reacts with NO to further decrease its bioavailability. CRFs are associated with increased vascular oxidative stress due to reactive oxygen species produced by uncoupled eNOS and other enzymes, including NADPH and mitochondrial oxidases.
One mechanism involved in the protective role of mineralocorticoid receptor blockade in endothelial function is increased NO bioavailability due to reduction in vascular oxidative stress and increased NO production [10, [42] [43] [44] . Decreased eNOS uncoupling has been demonstrated in humans [20 && ] and rats [10] after spironolactone treatment. This effect was associated with increased eNOS dimerization, expression of the chaperone HSP-90, and availability of BH 4 . These factors resulted in reduced superoxide generation and increased NO production. Spironolactone has also been shown to increase vascular superoxide dismutase and catalase expression, important antioxidants and to reduce expression of p47phox, the regulatory subunit of NADPH oxidase [20 Endothelial cell mineralocorticoid receptor modulates endothelial stiffness by regulating the epithelial sodium channel
The epithelial sodium channel (ENaC), a classical target of mineralocorticoid receptor in the kidney, has more recently been identified in vascular endothelial cells where it is also mineralocorticoid receptor-regulated and mediates endothelial sodium transport thereby contributing to vascular stiffness [45] . Aldosterone increases expression of ENaC in human endothelial cells in association with increased endothelial cell stiffness [46, 47] . Enhanced endothelial cell stiffness alters shear forces in the vasculature resulting in impaired NO production [48] . In the Western diet-induced obesity model, aortic stiffening and decreased NO production in female mice were blocked by spironolactone [42] . In this model, endothelial cell-specific mineralocorticoid receptor deletion prevented aortic stiffening, and this beneficial effect was associated with attenuation of endothelial ENaC promoter activity and gene expression and restoration of eNOS phosphorylation [25 & ]. These data support that regulation of ENaC by endothelial cell mineralocorticoid receptor may be an additional mediator of endothelial dysfunction in response to CRFs including obesity.
Contributions of endothelial cellmineralocorticoid receptor to vascular thrombosis and inflammation
When endothelial cells lining the vasculature become damaged by cardiac risk factors, they also become dysfunctional in their anti-inflammatory and antithrombotic functions, thereby contributing to development of atherosclerosis and its complications, myocardial infarction, and stroke. Overexpression or activation of mineralocorticoid receptor in endothelial cells in mice enhanced endothelial protein C receptor (EPCR) expression via a transcriptional mechanism, decreasing thrombin generation and attenuating vascular thrombosis [27] . These data suggest that mineralocorticoid receptor activation could be antithrombotic in the endothelium. However, this contrasts with previous studies demonstrating that aldosterone increases thrombosis in experimental models of vascular injury in mice [49, 50] . Once again these seemingly conflicting findings are consistent with the hypothesis that endothelial cell mineralocorticoid receptor has antithrombotic properties in healthy vessels, perhaps through increased NO bioavailability and EPCR, whereas in the presence of vascular injury or combined with risk factors, endothelial cell mineralocorticoid receptor may promote vascular thrombosis. Further studies are needed to test this hypothesis and explore potential mechanisms.
Substantial data support a role for endothelial cell mineralocorticoid receptor in vascular inflammation. In human coronary endothelial cells, activation of mineralocorticoid receptor by aldosterone increases transcription of the intercellular adhesion molecule-1 (ICAM-1) and promotes leucocyte adhesion [7] . This effect of endothelial cell mineralocorticoid receptor activation on ICAM-1 transcription is inhibited by estrogen activation of the estrogen receptor [35] . This interaction between mineralocorticoid receptor and estrogen receptor in endothelial cells may provide a mechanism for sex differences in the role of endothelial cell mineralocorticoid receptor in vascular dysfunction and inflammation. In Western diet-induced obese female mice, endothelial cell mineralocorticoid receptor deletion reduced aortic and myocardial oxidative stress, macrophage polarization to the M1 pro-inflammatory phenotype, and inflammatory cytokine levels while increasing expression of the anti-inflammatory cytokine IL- 10 [25 & ,26] . In contrast with the anti-inflammatory effects of endothelial cell mineralocorticoid receptor deletion in obese female mice, male endothelial cell mineralocorticoid receptor knockout mice were not protected from enhanced ICAM-1 expression, inflammatory cytokines, and T-cell recruitment in response to pressure overload-induced heart failure [51] . Endothelial cell mineralocorticoid receptor deficiency also did not ameliorate the mineralocorticoid/salt-induced renal inflammation and kidney injury in male mice [52 && ]. Significantly, obese female mice lost the protective effect of the endothelial estrogen receptor-a seen in healthy females [53 & ]. Therefore, similar to endothelial dysfunction, there are important sex differences in the proinflammatory effects of endothelial cell mineralocorticoid receptor activation that require further investigation.
CONCLUSION
In summary, mineralocorticoid receptor in endothelial cell may be vasculoprotective in normal physiology, but ample data support that in the setting of CRFs, including obesity, diabetes, and hypertension, endothelial cell mineralocorticoid receptor activation contributes to endothelial damage. Potential mechanisms include decreased NO bioavailability due to decreased NO production by eNOS and increased oxidative stress via eNOS uncoupling and NADPH oxidase activation and genomic regulation of ENaC and ICAM-1 to increase vascular stiffness and inflammation, respectively. There are important differences in the role of endothelial cell mineralocorticoid receptor in vascular dysfunction in males compared with females, conduit versus resistance vessels, and in distinct vascular beds. The detailed molecular mechanisms are only beginning to be elucidated and thus further study is needed to determine the ideal therapeutic interventions to limit the detrimental effects of endothelial cell mineralocorticoid receptor activation in patients at risk for cardiovascular disease. 
